Post-diagnostic aspirin exposure | Breast cancer-specific deaths n (%) | Controls n (%) | Unadjusted OR (95% CI) | P | AdjustedaOR (95% CI) | P | Additionally adjustedbfor stage and grade OR (95% CI) | P |
---|---|---|---|---|---|---|---|---|
No. prescriptions low dose | ||||||||
0 | 1,173 (81.7) | 4,641 (81.5) | 1.00 | 1.00 | 1.00 | |||
1 or more | 262 (18.3) | 1,056 (18.5) | 0.98 (0.83, 1.15) | 0.77 | 0.98 (0.81, 1.20) | 0.86 | 1.00 (0.71, 1.41) | 0.99 |
No. prescriptions low dose | ||||||||
0 | 1,173 (81.7) | 4,641 (81.5) | 1.00 | 1.00 | 1.00 | |||
1 to 11 | 117 (8.2) | 525 (9.2) | 0.88 (0.71, 1.09) | 0.25 | 0.90 (0.71, 1.16) | 0.42 | 0.80 (0.52, 1.24) | 0.32 |
12 or more | 145 (10.1) | 531 (9.3) | 1.08 (0.87, 1.33) | 0.48 | 1.08 (0.84, 1.39) | 0.57 | 1.28 (0.82, 2.01) | 0.27 |
No. tablets low dose | ||||||||
0 | 1,173 (81.7) | 4,641 (81.5) | 1.00 | 1.00 | 1.00 | |||
1 to 365 | 90 (6.3) | 385 (6.8) | 0.93 (0.72, 1.19) | 0.55 | 1.01 (0.77, 1.33) | 0.93 | 0.93 (0.57, 1.52) | 0.78 |
366 or more | 172 (12.0) | 671 (11.8) | 1.01 (0.83, 1.22) | 0.95 | 0.96 (0.76, 1.22) | 0.76 | 1.05 (0.69, 1.58) | 0.83 |
No. tablets low dose per day | ||||||||
0 | 1,173 | 4,641 (81.5) | 1.00 | 1.00 | 1.00 | |||
0 to 0.5 | 93 (6.5) | 370 (6.5) | 0.99 (0.78, 1.27) | 0.97 | 1.02 (0.78, 1.34) | 0.89 | 0.89 (0.56, 1.42) | 0.63 |
>0.5 | 169 (11.8) | 686 (12.0) | 0.97 (0.80, 1.17) | 0.72 | 0.96 (0.76, 1.21) | 0.73 | 1.10 (0.72, 1.67) | 0.67 |
No prescriptions high dose | ||||||||
0 | 1,415 (98.6) | 5,642 (99.0) | 1.00 | 1.00 | 1.00 | |||
1 or more | 20 (1.4) | 55 (1.0) | 1.47 (0.87, 2.46) | 0.15 | 1.15 (0.65, 2.04) | 0.62 | 1.11 (0.31, 4.04) | 0.87 |